530 related articles for article (PubMed ID: 26626772)
1. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Kim H; Lee SC; Kwon KY; Lee JH; Koh HJ; Byeon SH; Kim SS; Kim M; Lee CS
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1497-1503. PubMed ID: 26626772
[TBL] [Abstract][Full Text] [Related]
2. Peripapillary Choroidal Thickness Change of Polypoidal Choroidal Vasculopathy after Anti-vascular Endothelial Growth Factor.
Lee KH; Kim SH; Lee JM; Kang EC; Koh HJ
Korean J Ophthalmol; 2017 Oct; 31(5):431-438. PubMed ID: 28994269
[TBL] [Abstract][Full Text] [Related]
3. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
4. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Uzun S; Pehlivan E
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1651-1652. PubMed ID: 27117899
[No Abstract] [Full Text] [Related]
5. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
6. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
8. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
10. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Kanadani TCM; Veloso CE; Nehemy MB
Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
[TBL] [Abstract][Full Text] [Related]
11. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma.
Lee EK; Yu HG
Korean J Ophthalmol; 2019 Jun; 33(3):228-237. PubMed ID: 31179654
[TBL] [Abstract][Full Text] [Related]
13. DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Chang YC; Cheng CK
Retina; 2020 Jul; 40(7):1403-1411. PubMed ID: 31181038
[TBL] [Abstract][Full Text] [Related]
14. Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion.
Rayess N; Rahimy E; Ying GS; Pefkianaki M; Franklin J; Regillo CD; Ho AC; Hsu J
Am J Ophthalmol; 2016 Nov; 171():47-52. PubMed ID: 27567889
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
[TBL] [Abstract][Full Text] [Related]
16. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
Koizumi H; Yamagishi T; Yamazaki T; Kinoshita S
Am J Ophthalmol; 2013 Feb; 155(2):305-313.e1. PubMed ID: 23022162
[TBL] [Abstract][Full Text] [Related]
17. COMPARISON OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHIC CHANGES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ALONE OR IN COMBINATION WITH PHOTODYNAMIC THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY.
Teo KYC; Yanagi Y; Lee SY; Yeo IYS; Tan GSW; Mathur R; Chan CM; Wong TY; Cheung CMG
Retina; 2018 Sep; 38(9):1675-1687. PubMed ID: 28767554
[TBL] [Abstract][Full Text] [Related]
18. MORPHOLOGIC FEATURES ASSOCIATED WITH FIBROTIC SCARRING AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY.
Kim JH; Chang YS; Kim JW; Kim CG; Lee DW; Kim YJ
Retina; 2018 Nov; 38(11):2168-2176. PubMed ID: 28930802
[TBL] [Abstract][Full Text] [Related]
19. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
20. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
